Pregnancy on Oral Glucose Tolerance Test Implementation Status, Knowledge, and Anxiety Level

August 7, 2025 updated by: Özlem D Bozkurt, PhD, Ege University

The Effect of Video Education Given on Pregnancy on Oral Glucose Tolerance Test Implementation Status, Knowledge, and Anxiety Level

This study was planned to examine the effect of video education on pregnancy for oral glucose tolerance test implementation status, knowledge and anxiety level. The research was planned as a single-blind randomized controlled experimental study.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Hypothesis; H0: There is no difference between the OGTT knowledge level scores of primiparous pregnant women who received and did not receive video education.

H1: There is a difference between the OGTT knowledge level scores of primiparous pregnant women who received and did not receive video education.

H0: There is no difference between the status of having the OGTT, primiparous pregnant women who received and did not receive video education.

H1: There is a difference between the status of having the OGTT, primiparous pregnant women who received and did not receive video education.

H0: There is no difference between the mean scores of the State Anxiety Scale according to the video education status of the primiparous pregnant women who had OGTT.

H1: There is a difference between the mean scores of the State Anxiety Scale according to the video education status of the primiparous pregnant women who had OGTT.

H1: The anxiety level of pregnant women who had OGTT was lower than those who did not receive video education.

The research was planned as a single-blind randomized controlled experimental study. The homogeneity of the pregnant women in the education and control groups will be ensured according to age, education level and Instagram usage time. Considering the inclusion and exclusion criteria of the study, pregnant women will be divided into education and control groups by stratified randomization method. For this purpose, pregnant women who meet the criteria of the study will be assigned to the training and control group using a computer-assisted randomization program (https://www.random.org/). Pregnant women will not be informed about the groups they are in, and only the researcher will know which group they will be in, and single-blindness will be provided.

Dependent Variables The OGTT knowledge level of the pregnant women, their OGTT implementation status and the State Anxiety Inventory score average constitute the dependent variables of the study.

Independent variables The planned video OGTT training given to primiparous pregnant women constitutes the independent variable of the study.

Intermediate Variables Socio-demographic characteristics of pregnant women (age, occupation, marital status, family type, place of residence for the longest time, education level, income status, husband's occupation, husband's education level, husband's income), obstetric characteristics (gestational week, height, pregnancy Weight gained, family history of diabetes, history of miscarriage, presence of polycystic ovary syndrome), level of OGTT knowledge (the status of receiving information about OGTT, the people from whom they received information, the sufficient amount of information) constitute the intermediate variables of the research.

Informed Consent Form,Questionnaire for Descriptive Characteristics of Pregnants,Intention and Status of OGTT Questionnaire, Knowledge Level Form on Gestational Diabetes and Oral Glucose Tolerance Test (OGTT),State Anxiety Scale, Education Video Evaluation Form (for pilot group), Nickname card will be used in this study.

Study Type

Interventional

Enrollment (Actual)

114

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey, 34453
        • Sağlık Bilimleri Üniversitesi Sarıyer Hamidiye Etfal Eğitim ve Araştırma Hastanesi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 35 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Reading and understanding Turkish
  • literate
  • over 18 years old
  • under 35 years old
  • primiparous pregnant
  • before 24 weeks of pregnancy
  • having a computer or phone and able to access the internet
  • using Instagram
  • voluntarily agreed to participate in the study

Exclusion Criteria:

  • have a diagnosis of chronic diabetes mellitus (DM)
  • have an ectopic pregnancy,
  • want to leave the study voluntarily,
  • in the education group but do not watch all the education videos
  • have miscarriage or preterm birth
  • pregnant women who do not fill in the all forms in study
  • cannot be contacted during the research
  • who decide to continue their doctor's checkups in another hospital

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Education Group
  1. Follow-up (<24 weeks): "Questionnaire for Descriptive Characteristics of Pregnants" and "Informed Consent Form" and pretest application "Knowledge Level Form on the Pregnancy Diabetes and Oral Glucose Tolerance Test" will be made.
  2. Follow-up (<24. Week): Watching education videos:the education will end in 3 weeks. After that,post-test application "Knowledge Level Form on the Pregnancy Diabetes and Oral Glucose Tolerance Test" will be applied. They will be asked about their intention to have an OGTT.
  3. Follow-up (24-28. weeks): (Waiting after 75 mg dose is administered during OGTT): "State Anxiety Scale" will be applied. The OGTT implementation status of the pregnant woman will be recorded.
  4. Follow-up (30-34. weeks): 6 weeks after the video education, the "Knowledge Level Form on the Pregnancy Diabetes and Oral Glucose Tolerance Test" post-test application will be made.
Sharing of Planned Education Videos on Instagram In this research, the platform where planned video education will be shared was determined as "Instagram", which is the most used social media platform by pregnant women. In the Instagram user name "@ogttegitim" account, 6 education videos that will be created and shared.
No Intervention: Control Group
  1. Follow-up (<24 weeks): "Questionnaire for the Introductory Characteristics of Pregnants" and "Informed Consent Form", and pre-test application "Knowledge Level Form on the Pregnancy Diabetes and Oral Glucose Tolerance Test" will be made.
  2. Follow-up (before OGTT implementation at 24-28 weeks): A posttest application will be made"Knowledge Level Form on Pregnancy Diabetes and Oral Glucose Tolerance Test". It will be asked about their intention to have an OGTT.
  3. Follow-up (24-28. weeks) (Waiting after 75 mg dose is administered during OGTT):"State Anxiety Scale" will be applied face-to-face while the pregnant woman is waiting after 75 mg dose is administered during the OGTT application while she is with the pregnant woman on the test day. In addition, the OGTT implementation status of the pregnant woman will be recorded.
  4. Follow-up (30-34 weeks): The post-test application of the "Knowledge Level Form on Pregnancy Diabetes and Oral Glucose Tolerance Test" will be made.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Knowledge Level Form on the Pregnancy Diabetes and Oral Glucose Tolerance Test
Time Frame: before 24. pregnancy weeks and 30-34. pregnancy weeks
Pregnant women will respond to each information sentence by choosing one of the options "True", "False", "I don't know". It is planned that the form will consist of 25 or 30 items. The state of knowing the items before and after the education will be evaluated with a percentage.
before 24. pregnancy weeks and 30-34. pregnancy weeks
State Anxiety Scale
Time Frame: 24-28. pregnancy weeks
During the evaluation, a score between 1 (or -1) and 4 (or -4) is given for each item according to the positive or negative feature of the item, and the constant 50 is added to the total score to be obtained. The highest score is 80 and the lowest score is 20. The higher the total anxiety score, the higher the anxiety level of the person completing the inventory.
24-28. pregnancy weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Özlem Demirel Bozkurt, Assoc. Prof., Ege University Nursing Faculty

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 15, 2023

Primary Completion (Actual)

November 15, 2023

Study Completion (Actual)

April 22, 2024

Study Registration Dates

First Submitted

December 21, 2022

First Submitted That Met QC Criteria

January 9, 2023

First Posted (Actual)

January 17, 2023

Study Record Updates

Last Update Posted (Actual)

August 12, 2025

Last Update Submitted That Met QC Criteria

August 7, 2025

Last Verified

February 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • EGE-OZLEM-35
  • Gülcan KARABULUT (Other Identifier: Ege University, Women Health Nursing, master degree student)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

We would like to publish it as an article. It has not yet been published in a journal.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gestational Diabetes

Clinical Trials on Video Education

Subscribe